Explore 14 articles covering in-depth insights and practical guidance on climate biotech: carbon-negative processes.
What's working, what isn't, and what's next, with the trade-offs made explicit. Focus on implementation trade-offs, stakeholder incentives, and the hidden bottlenecks.
Side-by-side evaluation of biological carbon removal approaches (engineered algae, enhanced weathering microbes, soil carbon biotech) versus chemical processes (DAC, mineral carbonation). Biological pathways offer costs of $50–150 per tonne CO₂ but face permanence challenges, while chemical routes achieve 1,000+ year storage at $250–600 per tonne.
A concrete implementation with numbers, lessons learned, and what to copy/avoid. Focus on unit economics, adoption blockers, and what decision-makers should watch next.
Detailed cost and ROI analysis for carbon-negative biotech ventures including engineered algae, methanotroph platforms, and microbial carbon mineralization. Early-stage companies require $5–30M in R&D before pilot deployment, with carbon credit revenues of $50–200 per tonne needed to reach breakeven within 7–12 years.
A practical primer: key concepts, the decision checklist, and the core economics. Focus on implementation trade-offs, stakeholder incentives, and the hidden bottlenecks.
A step-by-step rollout plan with milestones, owners, and metrics. Focus on KPIs that matter, benchmark ranges, and what 'good' looks like in practice.
Essential KPIs for Climate biotech: carbon-negative processes across sectors, with benchmark ranges from recent deployments and guidance on meaningful measurement versus vanity metrics.
The 5–8 KPIs that matter, benchmark ranges, and what the data suggests next. Focus on data quality, standards alignment, and how to avoid measurement theater.
A comprehensive state-of-play assessment for Climate biotech: carbon-negative processes, evaluating current successes, persistent challenges, and the most promising near-term developments.
A practitioner conversation: what surprised them, what failed, and what they'd do differently. Focus on unit economics, adoption blockers, and what decision-makers should watch next.
A rigorous look at the most persistent misconceptions about Climate biotech: carbon-negative processes, with evidence-based corrections and practical implications for decision-makers.
Myths vs. realities, backed by recent evidence and practitioner experience. Focus on KPIs that matter, benchmark ranges, and what 'good' looks like in practice.
Strategic analysis of value creation and capture in Climate biotech: carbon-negative processes, mapping where economic returns concentrate and which players are best positioned to benefit.
Signals to watch, value pools, and how the landscape may shift over the next 12–24 months. Focus on data quality, standards alignment, and how to avoid measurement theater.